Loading...
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry
BACKGROUND: Prognostic scoring systems are used to estimate the risk of mortality from metastatic renal cell carcinoma (mRCC). Outcomes from different therapies may vary within each risk group. These survival algorithms have been applied to assess outcomes in patients receiving T-cell checkpoint inh...
Na minha lista:
| Udgivet i: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6437874/ https://ncbi.nlm.nih.gov/pubmed/30917871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0567-3 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|